+8.07% for Injective as rapid move draws traders to take profit

Traders Union
All News
Crypto News
Injective gains 8.07% to $7.05 today

Highlights

INJ maintains strong bullish momentum, trading well above short-, medium-, and long-term support levels.
Momentum indicators confirm persistent buying strength, but overbought readings signal rising risk of near-term exhaustion.
Price is expected to consolidate between $6.80 and $7.20, with a low probability of further upside and elevated risk of a pullback.

Overbought signals intensify as bullish momentum nears exhaustion

SMA-20 is at $5.46, SMA-50 at $4.36, and SMA-200 at $4.24, with the Ichimoku Kijun level at $5.56 now acting as immediate support. Daily momentum signals—including MACD, ADX, and Awesome Oscillator—are in clear "Buy" mode, while oscillators such as RSI (77.92), CCI (196.41), BBP (1.44), and Stoch RSI (100) all indicate overbought conditions. The price opened with a gap and remains near the top of today's $6.851 $7.29 intraday range, reflecting pronounced volatility and buyer dominance, though there are significant signals of potential exhaustion.

Consolidation favored as overbought risks temper upward momentum

Over the next five sessions, INJ is likely to consolidate within a volatility band of $6.80 to $7.50, closely tracking recent momentum and sharp price swings. With price momentum high but strong overbought signals present, a further rapid advance has less than a 20% probability, making consolidation or a short-term reversal more likely. The baseline scenario expects sideways movement between $6.80 and $7.20 as the market digests previous gains. A sustained break above $7.29 could drive a test of $7.50, but overbought readings may restrict upside extensions, while profit-taking below $6.80 could lead to a more pronounced pullback.

Anton Kharitonov, expert at Traders Union, notes that Injective (INJ) is showing strong momentum but is now heavily overbought, with multiple indicators suggesting potential for a pause or pullback. He observes that the recent move lacks underlying news or fundamental catalysts, making the rally reliant on technical factors. The analyst remains cautious, expecting consolidation or limited upside in the near term. "With buyers in control but technical exhaustion clear, my base case is for INJ to move sideways or correct as the market digests these gains," says Kharitonov.

Earlier, analysts noted that Injective’s strong bullish momentum was tempered by overbought conditions and the potential for sideways consolidation. With current overbought signals persisting even as volatility remains elevated, traders should watch for a decisive move beyond the recent $7.29 high as a catalyst for renewed momentum or, conversely, a break below $6.80 signaling deeper retracement risk.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.